FIFA News Agency, May 30 / PRNewswire-Asianet /-- recently, Shandong Shengdi Pharmaceutical, a subsidiary of Hengrui Medicine, received the "Drug Clinical trial approval notice" on HRS-1893 tablets approved and issued by the State Drug Administration, and will carry out clinical trials in the near future. HRS-1893 inhibits myocardial hypercontraction through a special mechanism and is intended to be used in the treatment of hypertrophic cardiomyopathy and heart failure caused by myocardial hypertrophy.